Halobetasol/tazarotene

Halobetasol/tazarotene (Duobrii) is a topical combination drug used to treat plaque psoriasis. It combines 0.01% halobetasol propionate (a corticosteroid that reduces inflammation and suppresses the immune system) and 0.045% tazarotene (a retinoid that promotes normal skin cell turnover and has anti-inflammatory effects) in a lotion formulation. It was approved as a prescription drug by the U.S. Food and Drug Administration (FDA) in April 2019   and by Health Canada in June 2020.